Australian Government - Department of Health

Medical Services Advisory Committee (MSAC)

1342.1 - Oncotype DX breast cancer assay to quantify the risk of disease recurrence and predict adjuvant chemotherapy benefit (Resubmission)

The following documents are posted for review and comment by the Medical Services Advisory Committee (MSAC) and the various sub-committee members in relation to this application.
The documents on this page may not be accessible, should you require assistance accessing the information please contact the MSAC Secretariat at msac.secretariat@health.gov.au

Resubmissions:
A subsequent application has been submitted, please refer to the resubmitted application 1342.2
For information with respect to the original submission, please refer to the previous application 1342
Application Number1342.1
Application NameOncotype DX breast cancer assay to quantify the risk of disease recurrence and predict adjuvant chemotherapy benefit (Resubmission)
Description of Medical ServiceOncotype DX is a genomic test that predicts likelihood of response to adjuvant chemotherapy and 10-year cancer recurrence in patients with node-negative and node positive (1–3), oestrogen-receptor-positive(ER+), human epidermal growth factor receptor 2 negative(HER2-), invasive breast cancer.
Description of Medical ConditionOutside Australia, Oncotype DX is currently used in women with node-negative and node positive (1-3), oestrogen-receptor-positive, HER2 negative invasive early stage breast cancer.
Consultation ProtocolPlease see Application 1342
Final ProtocolPlease see Application 1342
Reports-
MSAC OutcomesPDF Version Public Summary Document (PDF 58 KB)
Word Version Public Summary Document (Word 143 KB)

Meetings for this Application

Meeting Type:Date:
PASCN/A
ESC 13 -14 February 2014
MSAC 3 - 4 April 2014

Page currency, Latest update: 06 April, 2016